Rani Therapeutics Announces Bioequivalence of Oral GLP-1/GLP-2 Dual Agonist RT-114
Rani Therapeutics announced positive preclinical data for RT-114, an oral formulation of ProGen’s GLP-1/GLP-2 dual agonist, PG-102, for obesity...
Nephrologists Embrace Aggressive IgA Nephropathy Treatment
Spherix’s recent study of 507 IgA nephropathy (IgAN) patients reveals a disconnect between treatment goals and real-world disease management,...
Sonnet Biotherapeutics’ SON-1010 Shows Promising Safety in Sarcoma Combination Trial
Sonnet BioTherapeutics announced positive safety data from an expansion cohort of its Phase 1 SB101 trial. The trial is...
Decoy Therapeutics’ Novel Inhibitors Show Promise Against Measles
Decoy Therapeutics, a preclinical biopharmaceutical company, has announced that its antiviral drug candidates, designed using its IMP3ACT™ platform, have...
Acu193 Alzheimer’s Trial Enrollment Complete
Acumen Pharmaceuticals has completed enrollment in its Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) for early-stage Alzheimer’s diseaseAlzheimer’s disease....
City of Hope & Calidi Biotherapeutics Phase 1 Trial Update on CLD-101
Calidi Biotherapeutics and City of Hope announced positive progress in a Phase 1 clinical trial for CLD-101, a neural...
Pleco PTX-252 Shows Promise in AML FDA Meeting
Pleco Therapeutics, a clinical-stage biopharmaceutical company, has received positive feedback from the FDA regarding its Investigational New Drug (IND)...
ABpro Announces Preclinical Data for Tetravalent Bispecific HER2xCD3 T-Cell Engager at AACR 2025
Abpro Holdings announced preclinical data for its HER2 x CD3 T-cell engager, ABP-102/CT-P72, will be presented at the American...
Quanta’s QTX3544: A Powerful New Oral Multi-KRAS Inhibitor
Quanta Therapeutics will present data on QTX3544, an oral, G12V-preferring, multi-KRAS inhibitor, at the 2025 AACR Annual Meeting. QTX3544...
Bolt Biotherapeutics Presents Promising BDC-1042 Data at AACR 2025
Bolt Biotherapeutics will present Phase 1 clinical trial data for BDC-3042, a dectin-2 agonist antibody targeting tumor-associated macrophages (TAMs),...